WO2017211216A1 - 稠合嘧啶哌啶环衍生物及其制备方法和应用 - Google Patents
稠合嘧啶哌啶环衍生物及其制备方法和应用 Download PDFInfo
- Publication number
- WO2017211216A1 WO2017211216A1 PCT/CN2017/086817 CN2017086817W WO2017211216A1 WO 2017211216 A1 WO2017211216 A1 WO 2017211216A1 CN 2017086817 W CN2017086817 W CN 2017086817W WO 2017211216 A1 WO2017211216 A1 WO 2017211216A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- alkyl
- group
- formula
- pharmaceutically acceptable
- Prior art date
Links
- VRQMAABPASPXMW-HDICACEKSA-N C[C@H](C1)N[C@@H](C)CN1c(cc1)ccc1C(Nc1cc(CCc2cc(OC)cc(OC)c2)n[nH]1)=O Chemical compound C[C@H](C1)N[C@@H](C)CN1c(cc1)ccc1C(Nc1cc(CCc2cc(OC)cc(OC)c2)n[nH]1)=O VRQMAABPASPXMW-HDICACEKSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims (18)
- 如下述通式(I)表示的化合物,或其药学上可接受的盐,式中:X为CR6或N;Y为CR6R7或C(=O);Z为CR6或N;R1选自H、卤素、羟基、-C1-C6烷基、-C1-C6烷氧基、-C1-C6烷硫基、-C3-C6环烷基、卤代C1-C6烷基、羟基C1-C6烷基、-(CH2)n-NR6R7或可任选被一个或多个选自卤素、羟基、-C1-C6烷基、-C1-C6烷氧基、-C1-C6烷硫基、-NH2取代的C3-C6环烷基或4至7元杂环烷基;R2选自H、卤素、羟基、-C1-C6烷基、-C1-C6烷氧基或-C3-C6环烷基;R3、R4、R5各自独立地选自H、卤素、羟基、-C1-C6烷基、-C1-C6烷氧基、-C3-C6环烷基、-O-C3-C6环烷基、-C1-C6烷硫基、卤代C1-C6烷基、羟基C1-C6烷基、-C(=O)-NR6R7、-NR6R7、-OC(=O)R6、-COOR6、-NR6C(=O)R7、-NR6COOR7、-OSO2R6;R6、R7各自独立地选自H、-C1-C6烷基、-C1-C6烷氧基、-C3-C6环烷基或-C1-C6烷硫基;n为0、1、2、3、4。
- 如权利要求2所述的化合物或其药学上可接受的盐,其特征在于所述式(II)、式(IV)化合物的结构式中苯环取代基R6选自H、-C1-C6烷基或-C1-C6烷氧基。
- 如权利要求1或2所述的化合物或其药学上可接受的盐,其特征在于所述Y为CR6R7,其中R6、R7各自独立地选自H或-C1-C6烷基。
- 如权利要求1或2所述的化合物或其药学上可接受的盐,其特征在于所述R1选自H、卤素、羟基、-C1-C6烷基、-C1-C6烷氧基、-C1-C6烷硫基、-C3-C6环烷基、卤代C1-C6烷基、羟基C1-C6烷基、 -(CH2)n-NR6R7,其中R6、R7各自独立地选自H、-C1-C6烷基或-C1-C6烷氧基,n为0、1、2或3。
- 如权利要求5所述的化合物或其药学上可接受的盐,其特征在于所述R1选自H、羟基、-C1-C6烷基、-C1-C6烷氧基、-C3-C6环烷基、卤代C1-C6烷基、羟基C1-C6烷基、-(CH2)n-NR6R7,其中R6、R7各自独立地选自H、-C1-C6烷基或-C1-C6烷氧基,n为0、1或2。
- 如权利要求6所述的化合物或其药学上可接受的盐,其特征在于所述R1选自H、羟基、-C1-C4烷基、-C1-C4烷氧基、-C3-C6环烷基、卤代C1-C4烷基、羟基C1-C4烷基、-(CH2)n-NR6R7,其中R6、R7各自独立地选自H、-C1-C4烷基或-C1-C4烷氧基,n为0、1或2。
- 如权利要求1或2所述的化合物或其药学上可接受的盐,其特征在于所述R2选自H、卤素、羟基或-C1-C4烷基。
- 如权利要求1或2所述的化合物或其药学上可接受的盐,其特征在于所述R3、R4、R5各自独立地选自H、卤素、羟基、-C1-C6烷基、-C1-C6烷氧基、-C3-C6环烷基、-O-C3-C6环烷基、-C1-C6烷硫基、卤代C1-C6烷基、羟基C1-C6烷基、-C(=O)-NR6R7,且R3、R4、R5不同时为H,其中R6、R7各自独立地选自H、-C1-C6烷基或-C1-C6烷氧基。
- 如权利要求9所述的化合物或其药学上可接受的盐,其特征在于所述R3、R4、R5各自独立地选自H、卤素、羟基、-C1-C6烷基、-C1-C6烷氧基、-C(=O)-NR6R7,且R3、R4、R5不同时为H,其中R6、R7各自独立地选自H、-C1-C6烷基或-C1-C6烷氧基。
- 如权利要求10所述的化合物或其药学上可接受的盐,其特征在于所述R3、R4、R5各自独立地选自H、卤素、羟基、-C1-C4烷基、-C1-C4烷氧基、-C(=O)-NR6R7,且R3、R4、R5不同时为H,其中R6、R7各自独立地选自H、-C1-C4烷基或-C1-C4烷氧基。
- 如权利要求1所述的化合物或其药学上可接受的盐,它选自:6-(2,6-二氯-3,5-二甲氧基苯基)-N-(4-(4-乙基哌嗪-1-基)苯基)-5,6,7,8-四氢吡啶[4,3-d]嘧啶-2-胺;6-(2,6-二氯-3,5-二甲氧基苯基)-N-(4-(4-(2,2,2-三氟乙基)哌嗪-1-基)苯基)-5,6,7,8-四氢吡啶[4,3-d]嘧啶-2-胺;2-(4-(4-(6-(2,6-二氯-3,5-二甲氧基苯基)-5,6-7,8-四氢吡啶[4,3-d]嘧啶-2-基氨基)苯基)哌嗪-1-基)乙醇;6-(2,6-二氯-3,5-二甲氧基苯基)-N-(4-(4-(2-(二甲氨基)乙基)哌嗪-1-基)苯基)-5,6,7,8-四氢吡啶[4,3-d]嘧啶-2-胺;6-(2,6-二氯-3,5-二甲氧基苯基)-N-(4-(4-(二甲氨基)哌啶-1-基)苯基)-5,6,7,8-四氢吡啶[4,3-d]嘧啶-2-胺;6-(2,6-二氯-3,5-二甲氧基苯基)-N-(4-(4-环丙基哌嗪-1-基)苯基)-5,6,7,8-四氢吡啶[4,3-d]嘧啶-2-胺;1-(4-(6-(2,6-二氯-3,5-二甲氧基苯基)-5,6,7,8-四氢吡啶[4,3-d]嘧啶-2-基氨基)苯基-4-乙基哌嗪-2-酮;6-(2,6-二氯-3,5-二甲氧基苯基)-N-(6-(4-乙基哌嗪-1-基)吡啶-3-基)-5,6,7,8-四氢吡啶[4,3-d]嘧啶-2-胺;6-(2,6-二氯-3,5-二甲氧基苯基)-N-(6-(4-(二甲氨基)哌啶-1-基)吡啶-3-基)-5,6,7,8-四氢吡啶[4,3-d]嘧啶-2-胺;6-(2,6-二氯-3,5-二甲氧基苯基)-N-(4-(4-乙基哌嗪-1-基)-3-甲氧基苯基)-5,6,7,8-四氢吡啶[4,3-d]嘧啶-2-胺;4-氯-3-(2-(6-(4-乙基哌嗪-1-基)吡啶-3-基氨基)-7,8二氢吡啶[4,3-d]嘧啶-6(5H)-基)-5-甲氧基-N-甲基苯甲酰胺;4-氯-3-(2-(6-(4-乙基哌嗪-1-基)吡啶-3-基氨基)-7,8二氢吡啶[4,3-d]嘧啶-6(5H)-基)-N,5-二甲氧基苯甲酰胺;4-氯-3-(2-(4-(4-(二甲氨基)哌嗪-1-基)苯基氨基)-7,8二氢吡啶[4,3-d]嘧啶-6(5H)-基)-5-甲氧基-N-甲基苯甲酰胺;2-(4-(5-(6-(2,6-二氯-3,5-二甲氧基苯基)-5,6-7,8-四氢吡啶[4,3-d]嘧啶-2-基氨基)吡啶-2-基)哌嗪-1-基)乙醇;6-(2-氟-6-氯-3,5-二甲氧基苯基)-N-(4-(4-(二甲氨基)哌啶-1-基)苯基)-5,6,7,8-四氢吡啶[4,3-d]嘧啶-2-胺。
- 一种药物组合物,包括式(I)化合物或其药学上可接受的盐以及药学上可接受的载体。
- 权利要求1~12之任一项所述的化合物或其药学上可接受的盐用于制备药物的用途,该药物用于预防或治疗FGFR激酶介导的疾病状态或病症。
- 权利要求1~12之任一项所述的化合物或其药学上可接受的盐用于制备药物的用途,该药物用于预防或治疗癌症。
- 如权利要求17所述的用途,其特征在于所述癌症选自多发性骨 髓瘤、骨髓增生性疾病、子宫内膜癌、前列腺癌、膀胱癌、肺癌、卵巢癌、乳腺癌、胃癌、结肠直肠癌、口腔鳞状细胞癌、鳞状细胞癌、肝癌、肾癌、结肠癌和非小细胞肺癌。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018564881A JP6943886B2 (ja) | 2016-06-06 | 2017-06-01 | 縮合ピリミジノピペリジン誘導体、ならびにその製造方法および適用 |
CA3026592A CA3026592C (en) | 2016-06-06 | 2017-06-01 | Fused pyrimidine piperidine cyclic derivative, preparation process and use thereof |
US16/307,362 US10544144B2 (en) | 2016-06-06 | 2017-06-01 | Fused pyrimidine piperidine cyclic derivative, preparation process and use thereof |
KR1020197000056A KR102439603B1 (ko) | 2016-06-06 | 2017-06-01 | 융합된 피리미디노피페리딘 유도체, 및 그의 제조 방법 및 용도 |
EP17809655.8A EP3466948B1 (en) | 2016-06-06 | 2017-06-01 | Fused pyrimidinopiperidine derivative, and manufacturing method and application thereof |
CN201780006182.5A CN109071530B (zh) | 2016-06-06 | 2017-06-01 | 稠合嘧啶哌啶环衍生物及其制备方法和应用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610392343.6 | 2016-06-06 | ||
CN201610392343.6A CN107459519A (zh) | 2016-06-06 | 2016-06-06 | 稠合嘧啶哌啶环衍生物及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017211216A1 true WO2017211216A1 (zh) | 2017-12-14 |
Family
ID=60544467
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2017/086817 WO2017211216A1 (zh) | 2016-06-06 | 2017-06-01 | 稠合嘧啶哌啶环衍生物及其制备方法和应用 |
Country Status (7)
Country | Link |
---|---|
US (1) | US10544144B2 (zh) |
EP (1) | EP3466948B1 (zh) |
JP (1) | JP6943886B2 (zh) |
KR (1) | KR102439603B1 (zh) |
CN (2) | CN107459519A (zh) |
CA (1) | CA3026592C (zh) |
WO (1) | WO2017211216A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109705033B (zh) * | 2019-01-22 | 2021-03-30 | 杭州壹瑞医药科技有限公司 | N-杂芳基磺酰胺类衍生物及制备和应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101035769A (zh) * | 2004-06-24 | 2007-09-12 | 诺瓦提斯公司 | 作为激酶抑制剂的嘧啶脲衍生物 |
CN101611014A (zh) * | 2006-12-21 | 2009-12-23 | 阿斯利康(瑞典)有限公司 | 用作fgfr抑制剂的酰氨基吡唑类化合物 |
CN102858770A (zh) * | 2010-02-17 | 2013-01-02 | 德比欧法姆有限公司 | 双环化合物及其作为c-SRC/JAK激酶双重抑制剂的用途 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0961780B1 (en) | 1997-02-12 | 2007-04-11 | Electrophoretics Limited | Protein markers for lung cancer and use thereof |
ID27589A (id) * | 1998-05-26 | 2001-04-12 | Warner Lambert Comapny | Pirimidina bisiklik dan dihidropirimidina bisiklik 3,4 sebagai penghambat proliferasi selular |
WO2001060814A2 (en) | 2000-02-15 | 2001-08-23 | Sugen, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors |
UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
DK1775298T3 (da) | 2004-07-01 | 2013-05-21 | Daiichi Sankyo Co Ltd | Thienopyrazolderivat med PDE7-inhibitorisk aktivitet |
AU2007254491A1 (en) * | 2006-05-15 | 2007-11-29 | Irm Llc | Compositions and methods for FGF receptor kinases inhibitors |
JP2009542706A (ja) | 2006-06-29 | 2009-12-03 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ヒスタミンh3受容体の置換ベンズアミドモジュレーター |
US7737149B2 (en) | 2006-12-21 | 2010-06-15 | Astrazeneca Ab | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof |
AR078411A1 (es) | 2009-05-07 | 2011-11-09 | Lilly Co Eli | Compuesto de vinil imidazolilo y composicion farmaceutica que lo comprende |
GB0915196D0 (en) * | 2009-09-01 | 2009-10-07 | King S College London | Therapeutic compounds and their use |
GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
US8889870B2 (en) | 2012-03-12 | 2014-11-18 | Allergan, Inc. | Kinase inhibitors |
ME03300B (me) | 2012-06-13 | 2019-07-20 | Incyte Holdings Corp | Supsтituisana triciklična jedinjenja као inhibiтori fgfr |
WO2014026125A1 (en) * | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
GB201306610D0 (en) * | 2013-04-11 | 2013-05-29 | Almac Discovery Ltd | Pharmaceutical compounds |
DK2986610T5 (en) * | 2013-04-19 | 2018-12-10 | Incyte Holdings Corp | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS |
CN107624113B (zh) * | 2015-05-04 | 2020-10-23 | 豪夫迈·罗氏有限公司 | 作为HBsAg (HBV 表面抗原)和HBV DNA 生成的抑制剂用于治疗乙型肝炎病毒感染的四氢吡啶并嘧啶和四氢吡啶并吡啶类化合物 |
-
2016
- 2016-06-06 CN CN201610392343.6A patent/CN107459519A/zh active Pending
-
2017
- 2017-06-01 EP EP17809655.8A patent/EP3466948B1/en active Active
- 2017-06-01 CA CA3026592A patent/CA3026592C/en active Active
- 2017-06-01 US US16/307,362 patent/US10544144B2/en active Active
- 2017-06-01 WO PCT/CN2017/086817 patent/WO2017211216A1/zh unknown
- 2017-06-01 KR KR1020197000056A patent/KR102439603B1/ko active IP Right Grant
- 2017-06-01 JP JP2018564881A patent/JP6943886B2/ja active Active
- 2017-06-01 CN CN201780006182.5A patent/CN109071530B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101035769A (zh) * | 2004-06-24 | 2007-09-12 | 诺瓦提斯公司 | 作为激酶抑制剂的嘧啶脲衍生物 |
CN101611014A (zh) * | 2006-12-21 | 2009-12-23 | 阿斯利康(瑞典)有限公司 | 用作fgfr抑制剂的酰氨基吡唑类化合物 |
CN102858770A (zh) * | 2010-02-17 | 2013-01-02 | 德比欧法姆有限公司 | 双环化合物及其作为c-SRC/JAK激酶双重抑制剂的用途 |
Non-Patent Citations (1)
Title |
---|
See also references of EP3466948A4 * |
Also Published As
Publication number | Publication date |
---|---|
JP6943886B2 (ja) | 2021-10-06 |
CN109071530A (zh) | 2018-12-21 |
US20190218213A1 (en) | 2019-07-18 |
CA3026592A1 (en) | 2017-12-14 |
EP3466948A1 (en) | 2019-04-10 |
EP3466948B1 (en) | 2021-01-20 |
US10544144B2 (en) | 2020-01-28 |
JP2019517567A (ja) | 2019-06-24 |
KR102439603B1 (ko) | 2022-09-01 |
KR20190015470A (ko) | 2019-02-13 |
CN107459519A (zh) | 2017-12-12 |
EP3466948A4 (en) | 2020-02-19 |
CN109071530B (zh) | 2021-08-17 |
CA3026592C (en) | 2021-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7181558B2 (ja) | Egfrモジュレーターとしての置換2-アミノピリミジン誘導体 | |
JP6431593B6 (ja) | ピリジニルアミノピリミジン誘導体、その製造方法、および用途 | |
CA3042960C (en) | Fgfr4 inhibitor, preparation method therefor and pharmaceutical use thereof | |
US20210008023A1 (en) | N4-phenyl-quinazoline-4 -amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | |
KR20080052630A (ko) | Raf 억제제 화합물 및 그의 사용 방법 | |
JP2010533700A (ja) | ピリミジン誘導体 | |
CN112638897B (zh) | 一种egfr激酶抑制剂及其制备方法和应用 | |
WO2017211216A1 (zh) | 稠合嘧啶哌啶环衍生物及其制备方法和应用 | |
KR20230068412A (ko) | Cbp/ep300 브로모도메인 억제제로서의 헤테로시클릭 화합물 | |
CN115894486B (zh) | 一种氢化吡啶并喹唑啉类化合物、组合物及其应用 | |
TWI820414B (zh) | 喹唑啉類化合物、製備方法及其應用 | |
TW200418853A (en) | Pyridoindolone derivatives substituted in the 3-position by a heterocyclic group, their preparation and their application in therapeutics | |
TW202415370A (zh) | 新穎三環衍生物化合物以及其應用 | |
JP2022545930A (ja) | Fgfr阻害剤とするピラゾール類誘導体及びその調製方法 | |
WO2020200154A1 (zh) | 一类噻吩并氮杂环类化合物、制备方法和用途 | |
NZ787350A (en) | Heterocyclic compounds as ret kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17809655 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3026592 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2018564881 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20197000056 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2017809655 Country of ref document: EP Effective date: 20190107 |